Efficacy and tolerance of one-third full dose bacillus Calmette-Guérin maintenance therapy every 3 months or 6 months: Two-year results of URO-BCG-4 multicenter study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and tolerance of one-third full dose bacillus Calmette-Guérin maintenance therapy every 3 months or 6 months: Two-year results of URO-BCG-4 multicenter study

Published:2014-09-25 Issue:1 Volume:22 Page:53-60
ISSN:0919-8172
Container-title:International Journal of Urology
language:en
Short-container-title:Int J Urol

Author:

Pfister Christian¹²,Kerkeni Walid¹,Rigaud Jerome³,Le Gal Sophie⁴,Saint Fabien⁵,Colombel Marc⁶,Guy Laurent⁷,Wallerand Herve⁸,Irani Jacques⁹,Soulie Michel¹⁰,

Affiliation:

1. Urology Department; Charles Nicolle University Hospital; Rouen France

2. Clinical Investigation Center; Inserm 6204; Onco-Urology Group; Rouen France

3. Urology Department; Nantes University Hospital; Nantes France

4. Urology Department; Caen University Hospital; Caen France

5. Urology Department; Amiens University Hospital; Amiens France

6. Urology Department; Lyon University Hospital; Lyon France

7. Urology Department; Clermont Ferrand University Hospital; Clermont-Ferrand France

8. Urology Department; Bordeaux University Hospital; Bordeaux France

9. Urology Department; Poitiers University Hospital; Poitiers France

10. Urology Department; Toulouse University Hospital; Toulouse France

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/iju.12609/fullpdf

Reference24 articles.

1. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials;Sylvester;J. Urol.,2002

2. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity;Bohle;J. Urol.,2003

3. Recommendations Onco-Urology 2010: urothelial tumors;Pfister;Prog. Urol.,2010

4. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update;Hall;J. Urol.,2007

5. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized South West Oncology Group study;Lamm;J. Urol.,2000

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Impact of Dose Reduction of Bacillus Calmette–Guerin on Oncological Outcomes and Toxicity in Non-Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis;Bladder Cancer;2023-09-25

2. NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022;Journal of the National Comprehensive Cancer Network;2022-08

3. Recommandations du Comité de cancérologie de l’Association Française d’Urologie (CC-AFU) pour la bonne pratique des instillations intravésicales de mitomycine C, d’épirubicine et de BCG pour le traitement des tumeurs de la vessie n’infiltrant pas le muscle (TVNIM);Progrès en Urologie;2022-04

4. Recommandations des Comités de cancérologie (CC-AFU) et d’infectiologie (CI-AFU) de l’Association française d’urologie pour la prise en charge effets indésirables et complications du BCG;Progrès en Urologie;2022-03

5. Did the Scientific Innovations in the Management of Non-Muscle Invasive Bladder Cancer Patients Improve the Outcome during the Last 2 Decades?;Open Journal of Urology;2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3